Medpace Holdings, Inc. $MEDP Shares Purchased by Ethic Inc.

Key Points

• Ethic Inc. increased its stake in Medpace Holdings, Inc. by 199.1% in the first quarter, bringing its total ownership to 2,324 shares valued at approximately $692,000.
• Analysts have mixed ratings for Medpace, with two buy ratings, nine hold ratings, and three sell ratings; the company currently has a consensus price target of $406.60.
• Insider transactions included a significant sale by VP Susan E. Burwig, who sold 7,500 shares for approximately $3.38 million, which represents a decline in her ownership stake by 11.54%.

Ethic Inc. increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 199.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,324 shares of the company's stock after purchasing an additional 1,547 shares during the period. Ethic Inc.'s holdings in Medpace were worth $692,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Whittier Trust Co. grew its stake in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares in the last quarter. Colonial Trust Co SC boosted its stake in Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after acquiring an additional 105 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Medpace in the first quarter valued at $60,000. Assetmark Inc. boosted its stake in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after acquiring an additional 43 shares in the last quarter. Finally, True Wealth Design LLC boosted its stake in Medpace by 52.7% in the fourth quarter. True Wealth Design LLC now owns 258 shares of the company's stock valued at $86,000 after acquiring an additional 89 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Performance

NASDAQ MEDP traded up $10.30 during mid-day trading on Friday, reaching $463.64. 328,935 shares of the stock were exchanged, compared to its average volume of 424,882. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30. The business's fifty day simple moving average is $378.86 and its 200 day simple moving average is $335.05. The stock has a market capitalization of $13.02 billion, a PE ratio of 34.47, a PEG ratio of 2.92 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same quarter last year, the business earned $2.75 earnings per share. Medpace's revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of research reports. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and upped their target price for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Mizuho increased their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Robert W. Baird increased their price target on shares of Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Barclays increased their target price on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Finally, Truist Financial increased their target price on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Reduce" and an average target price of $406.60.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 48,487 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the completion of the sale, the chief executive officer owned 962,615 shares of the company's stock, valued at approximately $434,803,569.35. The trade was a 4.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at $4,654,350. This trade represents a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 114,450 shares of company stock worth $51,791,251 over the last three months. Insiders own 20.30% of the company's stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.